A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

        1 2 3 4 | Last   [Sort by number of followers]   [Restore default list]

  Subjects -> PHARMACY AND PHARMACOLOGY (Total: 653 journals)
Showing 1 - 200 of 253 Journals sorted alphabetically
AAPS Journal     Hybrid Journal   (Followers: 35)
AAPS Open     Open Access   (Followers: 5)
AAPS PharmSciTech     Hybrid Journal   (Followers: 10)
AboutOpen     Open Access  
ACS Pharmacology & Translational Science     Hybrid Journal   (Followers: 4)
Acta Pharmaceutica     Open Access   (Followers: 7)
Acta Pharmaceutica Indonesia     Open Access   (Followers: 2)
Acta Pharmaceutica Sinica B     Open Access   (Followers: 4)
Acta Pharmacologica Sinica     Hybrid Journal   (Followers: 5)
Acta Physiologica Hungarica     Full-text available via subscription   (Followers: 4)
Actualites Pharmaceutiques     Full-text available via subscription   (Followers: 7)
Actualites Pharmaceutiques Hospitalieres     Full-text available via subscription   (Followers: 3)
Advanced Drug Delivery Reviews     Hybrid Journal   (Followers: 214)
Advanced Herbal Medicine     Open Access   (Followers: 8)
Advanced Therapeutics     Hybrid Journal   (Followers: 1)
Advances in Antiviral Drug Design     Full-text available via subscription   (Followers: 3)
Advances in Drug Research     Full-text available via subscription   (Followers: 27)
Advances in Pharmaceutical Sciences     Full-text available via subscription   (Followers: 22)
Advances in Pharmacoepidemiology & Drug Safety     Open Access   (Followers: 5)
Advances in Pharmacological and Pharmaceutical Sciences     Open Access   (Followers: 9)
Advances in Pharmacology     Full-text available via subscription   (Followers: 18)
Advances in Pharmacology and Pharmacy     Open Access   (Followers: 11)
Advances in Traditional Medicine     Hybrid Journal   (Followers: 8)
Adverse Drug Reaction Bulletin     Full-text available via subscription   (Followers: 6)
African Journal of Pharmacy and Pharmacology     Open Access   (Followers: 9)
AJP : The Australian Journal of Pharmacy     Full-text available via subscription   (Followers: 17)
Alternatives to Laboratory Animals     Full-text available via subscription   (Followers: 10)
American Journal of Cardiovascular Drugs     Hybrid Journal   (Followers: 21)
American Journal of Drug Discovery and Development     Open Access   (Followers: 5)
American Journal of Geriatric Pharmacotherapy     Full-text available via subscription   (Followers: 13)
American Journal of Health-System Pharmacy     Full-text available via subscription   (Followers: 66)
American Journal of Pharmaceutical Education     Open Access   (Followers: 13)
American Journal of Pharmacological Sciences     Open Access   (Followers: 2)
American Journal of Pharmacology and Toxicology     Open Access   (Followers: 24)
American Journal of Therapeutics     Hybrid Journal   (Followers: 15)
Analytical Methods     Full-text available via subscription   (Followers: 13)
Annales de Toxicologie Analytique     Open Access  
Annales Pharmaceutiques Francaises     Full-text available via subscription   (Followers: 3)
Annals of Pharmacotherapy     Hybrid Journal   (Followers: 56)
Annual Review of Pharmacology and Toxicology     Full-text available via subscription   (Followers: 35)
Anti-Infective Agents     Hybrid Journal   (Followers: 6)
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry     Hybrid Journal   (Followers: 5)
Antibiotics     Open Access   (Followers: 9)
Antibiotiques     Full-text available via subscription  
Antibody Therapeutics     Open Access   (Followers: 1)
Antiviral Chemistry and Chemotherapy     Open Access   (Followers: 2)
Antiviral Research     Hybrid Journal   (Followers: 8)
Applied Clinical Research, Clinical Trials and Regulatory Affairs     Hybrid Journal   (Followers: 2)
Applied Clinical Trials     Full-text available via subscription   (Followers: 7)
Arabian Journal of Medicinal and Aromatic Plants     Open Access   (Followers: 4)
Archiv der Pharmazie     Hybrid Journal   (Followers: 3)
Archives of Drug Information     Hybrid Journal   (Followers: 5)
Archives of Pharmacal Research     Full-text available via subscription   (Followers: 2)
Archives of Pharmacy and Pharmaceutical Sciences     Open Access   (Followers: 7)
Archives of Pharmacy Practice     Open Access   (Followers: 12)
Archives of Razi Institute     Open Access  
Archivos Venezolanos de Farmacología y Terapéutica     Open Access  
Ars Pharmaceutica     Open Access   (Followers: 1)
Asian Journal of Medical and Pharmaceutical Researches     Open Access   (Followers: 2)
Asian Journal of Pharmaceutical Research and Health Care     Open Access   (Followers: 4)
Asian Journal of Pharmaceutical Sciences     Open Access   (Followers: 3)
Asian Journal of Pharmaceutics     Open Access   (Followers: 4)
Asian Journal of Research in Medical and Pharmaceutical Sciences     Open Access   (Followers: 1)
ASSAY and Drug Development Technologies     Hybrid Journal   (Followers: 4)
Australian Journal of Herbal Medicine     Full-text available via subscription   (Followers: 5)
Australian Pharmacist     Full-text available via subscription   (Followers: 6)
Autonomic & Autacoid Pharmacology     Hybrid Journal  
Avicenna Journal of Phytomedicine     Open Access   (Followers: 1)
Bangladesh Journal of Pharmacology     Open Access  
Bangladesh Journal of Physiology and Pharmacology     Open Access  
Bangladesh Pharmaceutical Journal     Full-text available via subscription   (Followers: 3)
Basic & Clinical Pharmacology & Toxicology     Hybrid Journal   (Followers: 13)
Behavioural Pharmacology     Hybrid Journal   (Followers: 3)
Bioanalysis     Full-text available via subscription   (Followers: 12)
Biochemical Pharmacology     Hybrid Journal   (Followers: 11)
Biochemistry & Pharmacology : Open Access     Open Access   (Followers: 5)
BioDrugs     Full-text available via subscription   (Followers: 10)
Biological & Pharmaceutical Bulletin     Full-text available via subscription   (Followers: 6)
Biomedical and Environmental Sciences     Full-text available via subscription   (Followers: 3)
Biomedicine & Pharmacotherapy     Full-text available via subscription   (Followers: 3)
Biometrical Journal     Hybrid Journal   (Followers: 10)
Biopharm International     Full-text available via subscription   (Followers: 19)
Biopharmaceutics and Drug Disposition     Hybrid Journal   (Followers: 11)
Biotemas     Open Access  
BMC Pharmacology     Open Access   (Followers: 3)
BMC Pharmacology & Toxicology     Open Access   (Followers: 7)
Botanics : Targets and Therapy     Open Access   (Followers: 6)
Brazilian Journal of Pharmaceutical Sciences     Open Access   (Followers: 2)
British Journal of Clinical Pharmacology     Hybrid Journal   (Followers: 33)
British Journal of Pharmacology     Hybrid Journal   (Followers: 20)
British Journal of Pharmacy (BJPharm)     Open Access   (Followers: 6)
Bulletin of Faculty of Pharmacy, Cairo University     Open Access   (Followers: 8)
CADTH Technology Overviews     Free  
Canadian Journal of Pain     Open Access   (Followers: 2)
Canadian Journal of Physiology and Pharmacology     Hybrid Journal   (Followers: 2)
Canadian Pharmacists Journal / Revue des Pharmaciens du Canada     Hybrid Journal   (Followers: 3)
Cancer Biotherapy & Radiopharmaceuticals     Hybrid Journal   (Followers: 1)
Cancer Chemotherapy and Pharmacology     Hybrid Journal   (Followers: 7)
Cardiovascular Drugs and Therapy     Hybrid Journal   (Followers: 16)
Cardiovascular Therapeutics     Open Access   (Followers: 2)
Cephalalgia Reports     Open Access   (Followers: 4)
Chemical and Pharmaceutical Bulletin     Full-text available via subscription   (Followers: 3)
Chemical Research in Toxicology     Hybrid Journal   (Followers: 25)
ChemMedChem     Hybrid Journal   (Followers: 11)
Chemotherapy     Full-text available via subscription   (Followers: 3)
Chinese Herbal Medicines     Full-text available via subscription   (Followers: 1)
Chinese Journal of Pharmaceutical Analysis     Full-text available via subscription  
Ciencia e Investigación     Open Access  
Ciência Equatorial     Open Access   (Followers: 1)
Clinical and Experimental Pharmacology and Physiology     Hybrid Journal   (Followers: 8)
Clinical and Translational Science     Open Access   (Followers: 5)
Clinical Cancer Drugs     Hybrid Journal   (Followers: 2)
Clinical Drug Investigation     Full-text available via subscription   (Followers: 8)
Clinical Immunology, Endocrine & Metabolic Drugs     Hybrid Journal  
Clinical Medicine Insights : Therapeutics     Open Access   (Followers: 1)
Clinical Neuropharmacology     Hybrid Journal   (Followers: 4)
Clinical Pharmacist     Partially Free   (Followers: 11)
Clinical Pharmacokinetics     Full-text available via subscription   (Followers: 30)
Clinical Pharmacology & Therapeutics     Hybrid Journal   (Followers: 48)
Clinical Pharmacology in Drug Development     Hybrid Journal   (Followers: 6)
Clinical Pharmacology: Advances and Applications     Open Access   (Followers: 6)
Clinical Research and Regulatory Affairs     Hybrid Journal   (Followers: 17)
Clinical Therapeutics     Hybrid Journal   (Followers: 34)
Clinical Toxicology     Hybrid Journal   (Followers: 21)
Clinical Trials     Hybrid Journal   (Followers: 21)
CNS & Neurological Disorders - Drug Targets     Hybrid Journal   (Followers: 3)
CNS Drug Reviews     Open Access   (Followers: 5)
CNS Drugs     Full-text available via subscription   (Followers: 8)
Combination Products in Therapy     Open Access  
Consultant Pharmacist     Full-text available via subscription   (Followers: 3)
Consumer Drugs     Full-text available via subscription  
Contract Pharma     Full-text available via subscription  
Cosmetics     Open Access   (Followers: 5)
CPT : Pharmacometrics & Systems Pharmacology     Open Access   (Followers: 9)
Critical Reviews in Clinical Laboratory Sciences     Hybrid Journal   (Followers: 19)
Critical Reviews in Therapeutic Drug Carrier Systems     Full-text available via subscription   (Followers: 5)
Critical Reviews in Toxicology     Hybrid Journal   (Followers: 25)
Current Bioactive Compounds     Hybrid Journal  
Current Cancer Therapy Reviews     Hybrid Journal   (Followers: 6)
Current Clinical Pharmacology     Hybrid Journal   (Followers: 4)
Current Computer-Aided Drug Design     Hybrid Journal   (Followers: 1)
Current Drug Delivery     Hybrid Journal   (Followers: 9)
Current Drug Discovery Technologies     Hybrid Journal   (Followers: 6)
Current Drug Metabolism     Hybrid Journal   (Followers: 5)
Current Drug Safety     Hybrid Journal   (Followers: 9)
Current Drug Targets     Hybrid Journal   (Followers: 7)
Current Drug Therapy     Hybrid Journal   (Followers: 3)
Current Enzyme Inhibition     Hybrid Journal   (Followers: 2)
Current Issues in Pharmacy and Medical Sciences     Open Access   (Followers: 6)
Current Medical Science     Hybrid Journal   (Followers: 3)
Current Medicinal Chemistry     Hybrid Journal   (Followers: 14)
Current Metabolomics     Hybrid Journal   (Followers: 6)
Current Molecular Pharmacology     Hybrid Journal  
Current Nanomedicine     Hybrid Journal   (Followers: 1)
Current Nanoscience     Hybrid Journal  
Current Neuropharmacology     Hybrid Journal   (Followers: 2)
Current Opinion in Pharmacology     Hybrid Journal   (Followers: 10)
Current Pharmaceutical Analysis     Hybrid Journal   (Followers: 3)
Current Pharmaceutical Biotechnology     Hybrid Journal   (Followers: 11)
Current Pharmaceutical Design     Hybrid Journal   (Followers: 13)
Current Pharmacogenomics and Personalized Medicine     Hybrid Journal   (Followers: 3)
Current Pharmacology Reports     Hybrid Journal   (Followers: 1)
Current Protocols in Pharmacology     Hybrid Journal  
Current Psychopharmacology     Hybrid Journal   (Followers: 1)
Current Radiopharmaceuticals     Hybrid Journal   (Followers: 1)
Current Research in Drug Discovery     Open Access   (Followers: 1)
Current Therapeutic Research     Open Access   (Followers: 10)
Current trends in Biotechnology and Pharmacy     Open Access   (Followers: 10)
Current Vascular Pharmacology     Hybrid Journal   (Followers: 5)
DARU Journal of Pharmaceutical Sciences     Open Access   (Followers: 4)
Dhaka University Journal of Pharmaceutical Sciences     Open Access   (Followers: 4)
Die Pharmazie - An International Journal of Pharmaceutical Sciences     Full-text available via subscription   (Followers: 10)
Discovery Phytomedicine     Open Access   (Followers: 4)
Dose-Response     Open Access  
Drug Analytical Research     Open Access  
Drug and Chemical Toxicology     Hybrid Journal   (Followers: 16)
Drug and Therapeutics Bulletin     Hybrid Journal   (Followers: 9)
Drug Delivery     Open Access   (Followers: 12)
Drug Delivery and Translational Research     Hybrid Journal   (Followers: 2)
Drug Delivery Letters     Hybrid Journal  
Drug Design, Development and Therapy     Open Access   (Followers: 4)
Drug Development and Industrial Pharmacy     Hybrid Journal   (Followers: 34)
Drug Development Research     Hybrid Journal   (Followers: 19)
Drug Discovery Today     Full-text available via subscription   (Followers: 191)
Drug Discovery Today: Disease Mechanisms     Full-text available via subscription   (Followers: 8)
Drug Discovery Today: Disease Models     Full-text available via subscription   (Followers: 10)
Drug Discovery Today: Technologies     Full-text available via subscription   (Followers: 13)
Drug Discovery Today: Therapeutic Strategies     Full-text available via subscription   (Followers: 12)
Drug Metabolism and Disposition     Hybrid Journal   (Followers: 17)
Drug Metabolism and Personalized Therapy     Hybrid Journal   (Followers: 3)
Drug Metabolism and Pharmacokinetics     Full-text available via subscription   (Followers: 6)
Drug Metabolism Letters     Hybrid Journal   (Followers: 4)
Drug Metabolism Reviews     Hybrid Journal   (Followers: 10)
Drug Research     Hybrid Journal   (Followers: 3)
Drug Resistance Updates     Hybrid Journal   (Followers: 3)
Drug Safety     Full-text available via subscription   (Followers: 191)
Drug Safety - Case Reports     Open Access   (Followers: 3)
Drug Target Insights     Open Access  
Drug, Healthcare and Patient Safety     Open Access   (Followers: 12)
Drugs     Full-text available via subscription   (Followers: 234)

        1 2 3 4 | Last   [Sort by number of followers]   [Restore default list]

Similar Journals
Journal Cover
Chemotherapy
Journal Prestige (SJR): 0.524
Citation Impact (citeScore): 2
Number of Followers: 3  
 
  Full-text available via subscription Subscription journal
ISSN (Print) 0009-3157 - ISSN (Online) 1421-9794
Published by Karger Homepage  [120 journals]
  • Appropriate Number of Docetaxel Cycles in Castration-Resistant Prostate
           
    • Abstract: Background: The number of cycles of docetaxel required for castration-resistant prostate cancer (CRPC) is unclear. This study estimated peripheral neuropathy (PN) incidence and the optimal number of treatment cycles in patients receiving docetaxel for CRPC. Patients and Methods: The study retrospectively reviewed 82 patients receiving docetaxel for CRPC at an institution between January 2005 and January 2017. Docetaxel (70 or 75 mg/m2) was administered every 3 weeks, and prednisone 5 mg or dexamethasone 0.5 mg was administered twice a day. Results: PN (grade ≥2) was noted in 32 (39.0%) patients. The median cumulative dose of docetaxel associated with PN was 675 mg/m2. No factor significantly predicted the occurrence of PN. The prostate-specific antigen progression rate, prostate cancer-specific survival, and overall survival were significantly better with ≥8 cycles of docetaxel than with #x3c;8 cycles (p #x3c; 0.05). Conclusion: The incidence of PN is high, and 8 treatment cycles are optimal for patients receiving docetaxel for CRPC.
      Chemotherapy
      PubDate: Fri, 22 Jan 2021 09:35:56 +010
       
  • Rescue Therapy of Refractory Diffuse Large B-Cell Lymphomas BCL2 with
           Venetoclax: Case Report
    • Abstract: Eleven years ago, a 64-year-old Caucasian man had LNH Follicular 3a, IV A stage, FLIPI 2 as a prognostic index of follicular lymphoma. He received 8 cycles of RCHOP followed by rituximab maintenance, with complete remission. Due to a systemic recurrence, a new treatment schedule (RCOMP, 6 cycles) was introduced with partial remission persisting during a long-term maintenance treatment with rituximab. Three years ago, LNH Follicular 3a progressed into GC type diffuse large B-cell lymphomas (DLBCL); 6 cycles of rituximab and bendamustine were followed by R-ICE and R OXALI DHAP treatments without beneficial effect. Due to the worse general condition (ECOG 3–4), the patient was treated with pixantrone (6 cycles) until July 10, 2019, with a partial response. On Jan 13, 2020, an extreme compassioned treatment with venetoclax alone was started; this drug was well tolerated and provided a satisfactory clinical and laboratory improvement. In June 2020, however, he developed bone marrow toxicity and septic fever. Nasal and pharyngeal secretions were SARS-CoV-2 RNA negative. Blood cultures for mycotic agents and Gram-positive, Gram-negative, and anaerobic bacteria were negative, but few days later, the patients died of sepsis due to unidentified agents. The use of venetoclax as a single drug to treat DLBCL BCL2 patients deserves further investigation.
      Chemotherapy
      PubDate: Thu, 21 Jan 2021 07:52:55 +010
       
  • Minimal Residual Disease Eradication by Azacitidine Maintenance in a
           Patient with Core-Binding Factor Acute Myeloid Leukemia
    • Abstract: Although core-binding factor AML (CBF-AML) has a favorable outcome, disease relapses occur in up to 35% of patients. Minimal residual disease (MRD) monitoring is one of the important tools to enable us to identify patients at high risk of relapse. Real-time quantitative PCR allows MRD to be measured with high sensitivity in CBF-AML. If the patient with CBF-AML is in complete morphologic remission but MRD positive at the end of treatment, what to do for those is still uncertain. Preemptive intervention approaches such as allogeneic hematopoietic stem cell transplantation or intensive chemotherapy could be an option or another strategy might be just follow-up until overt relapse developed. Although using hypomethylating agents as a maintenance therapy has not been widely explored, here, we report a case with CBF-AML who was still positive for MRD after induction/consolidation therapies and whose MRD was eradicated by azacitidine maintenance.
      Chemotherapy
      PubDate: Mon, 14 Dec 2020 14:12:32 +010
       
  • “Door to Treatment” Outcomes of Cancer Patients during the
           COVID-19 Pandemic
    • Abstract: Background: The novel coronavirus disease 2019 has become a worldwide threat. We aimed to explore reflections of these unexpected changes to newly diagnosed cancer patients. Method: We searched the 2 months after the index case of our country. The first admission day and the first day of intravenous treatment of newly diagnosed patients were recorded. Results: In the 60 days measured during the pandemic, the total number of patients on polyclinics was 159/weekdays, and the total applied chemotherapy cycles were 276/week. For comparison, the total numbers in the previous year were 267/weekday and 363/week for polyclinic and applied chemotherapy cycles, respectively. The total number of newly admitted patients in 2020 was 283. For comparison, the number of new patients in the same 60-day period in 2019 was 495. Patients who were admitted for adjuvant treatment required a median of 8 days for the first course, those who were admitted for neoadjuvant treatment required 12 days, and metastatic patients required 14 days; there were no significant differences between treatment types (p = 0.233). However, the median treatment time was 11.5 and 17 days, in 2020 and in 2019, respectively. A significant difference was observed between the 2 groups (p #x3c; 0.001). Conclusion: The effective shift of workers and accurate regulations have not resulted in apparent delays in patient care. While a decrease in the number of patients has detected, faster healthcare service was introduced to newly diagnosed patients. The reason for the decrease in the number of patients should be investigated with new studies.
      Chemotherapy
      PubDate: Fri, 04 Dec 2020 09:34:31 +010
       
  • Oncologic Outcomes of Salvage Chemotherapy in Patients with Recurrent or
           Metastatic Lesions after Radical Nephroureterectomy: A Multi-Institutional
           Retrospective Study
    • Abstract: Background: Radical nephroureterectomy (RNU) is the standard treatment for patients with upper tract urothelial carcinoma (UTUC). However, approximately 25% of patients experience recurrence or metastasis after RNU. This study evaluated the clinical outcome and efficacy of salvage chemotherapy (SC) after recurrence or metastasis. Patients and Methods: Of the 441 nonmetastatic UTUC patients who underwent RNU, 147 patients with recurrent or metastatic lesions were analyzed; patients with bladder cancer recurrence were excluded. Time from disease recurrence or metastasis to cancer-specific survival (CSS) was estimated by the Kaplan-Meier method. Multivariate analyses were performed with the Cox proportional hazards regression model, controlling for the effects of clinicopathological factors. Results: The median time from RNU to disease recurrence or metastasis was 13.2 months. In the recurrent or metastatic sites, 31 cases (21%) were liver. In multivariate analyses, pT stage (≥pT3), time to recurrence (#x3c;12 months), and liver metastasis were independently predictive factors. In the risk stratification model for CSS after recurrence, patients were categorized into 2 groups based on pT stage, time to recurrence, and liver metastasis. The low-risk group (0–1 risk factors) included 87 patients, and the high-risk group (2–3 risk factors) included 60 patients. In the high-risk group, 27 patients received SC. The probability of CSS after recurrence or metastasis was higher in patients in the SC group compared to the non-SC group (9.5 vs. 3.7 months; p #x3c; 0.001). Conclusion: Two or more risk factors defined the high-risk group for patients with recurrence or metastasis after RNU. SC was associated with improved survival in patients with high-risk UTUC.
      Chemotherapy
      PubDate: Mon, 30 Nov 2020 11:52:46 +010
       
  • Protein Disulfide Isomerase 4 Drives Docetaxel Resistance in Prostate
           Cancer
    • Abstract: Background: Protein disulfide isomerase 4 (PDIA4) has been reported to be closely associated with chemoresistance in several types of malignancies. But the pathogenic mechanisms of PDIA4 involved in docetaxel (DTX) resistance in prostate cancer (PCa) are still unknown. Hence, this study was conducted to evaluate the potential effect of PDIA4 on chemoresistance to DTX in PCa cells and to investigate the underlying mechanisms. Methods: Two types of DTX-resistant PCa cells, that is, DTX-resistant PC-3 cells (PC-3/DTXR) and C4-2B cells (C4-2B/DTXR) were developed, as well as the parental PC-3 and C4-2B cells were obtained to investigate these issues. Short hairpin RNAs targeting human PDIA4 to knockdown the expression of PDIA4 or PDIA4-expressing adenoviral vectors to overexpress the PDIA4 were transfected into PCa cells to study the underlying mechanisms of PDIA4 involving in PCa DTX resistance. Results: Results showed that PDIA4 exhibited a dramatic overexpression in PC-3/DTXR and C4-2B/DTXR cells. Down-regulation of PDIA4 by infecting PC-3/DTXR and C4-2B/DTXR cells with shPDIA4 lentivirus stimulated cell death by prompting apoptosis. Up-regulation of PDIA4 by infecting PC-3 and C4-2B cells with PDIA4-expressing adenovirus showed severer resistance to DTX. In addition, PDIA4 up-regulation induced phosphorylated protein kinase B (Akt) expression, while PDIA4 knockdown significantly inhibited the expression in PCa cells. Conclusions: Our study indicates that PDIA4 is a negative regulator of PCa cell apoptosis and plays a critical role in PCa DTX resistance by activating the Akt-signaling pathway. Thereby, it implies that targeting PDIA4 could be a potential adjuvant therapeutic approach against DTX resistance in PCa.
      Chemotherapy
      PubDate: Wed, 25 Nov 2020 13:58:45 +010
       
  • Diet and Chemotherapy: The Effects of Fasting and Ketogenic Diet on Cancer
           Treatment
    • Abstract: Introduction: Diet may influence various aspects of human health. In fact, it is well known that diet can favour or not the development of various human pathologies, like diabetes, hypertension, and hypercholesterolaemia. Interestingly, diet has an influence in cancer development too (e.g., this relation has been studied for pancreatic, colonic, gastric, and breast cancers). Between the mechanisms that could explain this relation, there is epigenetic. In fact, thanks to epigenetic reprogramming, certain substances introduced with diet could affect gene expression, especially of those genes involved in cells’ proliferation and growth. In recent years, some studies have been published about the role that diet could have on chemotherapy outcome. Especially, various studies have analysed the effects of fasting and ketogenic diet (KD) during chemotherapy. The aim of this study is to summarize scientific evidences about diet and its effects on chemotherapy on humans and to better understand if these approaches deserve to be further investigated and might be suitable and beneficial during cancer treatment. Materials and Methods: We performed an electronic literature search of the PubMed database, using the combination of following terms: “fasting” or “ketogenic” with “chemotherapy,” “cancer treatment.” We included studies on humans about fasting and KD during chemotherapy, excluding reviews, case series including #x3c;10 patients, studies conducted on animals or limited to radiotherapy treatment, and studies that were mostly about molecular mechanisms. Results/Discussion In our analysis we included 4 studies (1 randomized controlled trial, 1 retrospective study, and 2 prospective pilot studies) about KD and 4 studies (1 prospective cohort study, 1 case series report, and 2 randomized trials) about fasting during oncological treatments.
      Authors suggested an improvement of quality of life (QoL) and fatigue in patients under chemotherapy, especially in the 8 days after chemotherapy treatment. We found that both fasting and KD demonstrated to be tolerable and feasible during oncological treatments. Conversely, data about survival outcomes are still controversial, but it should be underlined that it was not the outcome of these preliminary studies. Conclusions: All comparatives studies have demonstrated that even fasting then KD results in a reduction of collateral effects of adjuvant chemotherapy (due to reduction of drugs toxicity) and a better QoL than in patients that follow no diet. Unfortunately, despite the fact that various laboratory and animal studies confirm advantages from KD and fasting, few data are today disposable on humans: further studies are needed to confirm data exposed in this review.
      Chemotherapy
      PubDate: Mon, 16 Nov 2020 07:45:54 +010
       
  • Modern Radiotherapy and Risk of Cardiotoxicity
    • Abstract: Despite the advancements of modern radiotherapy, radiation-induced heart disease remains a common cause of morbidity and mortality amongst cancer survivors. This review outlines the basic mechanism, clinical presentation, risk stratification, early detection, possible mitigation, and treatment of this condition.
      Chemotherapy
      PubDate: Tue, 13 Oct 2020 06:54:53 +020
       
  • HDAC3 Silencing Enhances Acute B Lymphoblastic Leukaemia Cells Sensitivity
           to MG-132 by Inhibiting the JAK/Signal Transducer and Activator of
           Transcription 3 Signaling Pathway
    • Abstract: Purpose: HDAC3, which is associated with smurf2, has been shown to be associated with poor prognosis in B-ALL. This study examined the efficacy of targeting HDAC3 combined with MG-132 as a possible therapeutic strategy for B-ALL patients. Methods: Real-time PCR and western blot were used to measure the expression of smurf2 and HDAC3 from B-ALL patients bone marrow samples. Sup-B15 and CCRF-SB cells were treated with MG-132, small interfering RNA of smurf2 or HDAC3. A plasmid designed to up-regulate smurf2 expression was transfected into B-ALL cells. Flow cytometry and western blot were used to measure variation due to these treatments in terms of apoptosis and cell cycle arrest. Results: Expression of Smurf2 and HDAC3 mRNA were inversely related in B-ALL patients. Up-regulation of smurf2 or MG-132 influenced HDAC3, further inhibiting the JAK/signal transducer and activator of transcription 3 (STAT3) signal pathway and inducing apoptosis in B-ALL cells. When we treated Sup-B15 and CCRF-SB cells with siHDAC3 and MG-132 for 24 h, silencing HDAC3 enhanced the apoptosis rate induced by MG-132 in B-ALL cells and further inhibited the JAK/STAT3 pathway. Furthermore, MG-132 was observed to cause G2/M phase arrest in B-ALL cells and inhibited the JAK/STAT3 pathway, leading to apoptosis. Conclusions: Silencing of HDAC3 enhanced the sensitivity of B-ALL cells to MG-132. The combination of targeting HDAC3 and MG-132 may provide a new avenue for clinical treatment of acute B lymphocytic leukaemia and improve the poor survival of leukaemia patients.
      Chemotherapy
      PubDate: Wed, 23 Sep 2020 13:36:33 +020
       
  • White Blood Cell Count Nadir and Duration of Aplasia Do Not Associate with
           Treatment Outcome in Adult Patients with Acute Myeloid Leukemia Undergoing
           Intensive Chemotherapy
    • Abstract: Introduction: Adult patients with acute myeloid leukemia (AML) are usually treated with intensive chemotherapy, leading to prolonged bone marrow aplasia. It is usually assumed that a short duration of aplasia could be a surrogate marker of poor therapeutic efficacy in clearing bone marrow blasts, especially in older patients. No studies have evaluated the usefulness of such a surrogate marker in younger AML patients treated with intensive chemotherapy. Materials and Methods: In the present study, we retrospectively assessed the role of white blood cell (WBC) count nadir and duration of aplasia in 68 patients with AML treated with intensive chemotherapy and potentially candidate to stem cell transplantation. Results: The median (interquartile range) bone marrow aplasia was 25 days, and the mean WBC count nadir from chemotherapy start was at day +12, whereas the median neutrophil recovery occurred at day +24. No significant differences were found between responders and nonresponders for mean aplasia duration (25 vs. 26 days, p value = 0.76), mean WBC count nadir (12 vs. 12 days, p value = 0.86), and median neutrophil recovery (24 vs. 24, p value = 0.67). Discussion: The present study evaluated the potential prognostic role of WBC count nadir and duration of aplasia, demonstrating that they are not associated with treatment outcomes in adult patients with AML treated with intensive chemotherapy. Therefore, a short duration of aplasia seems not linked to poor therapeutic efficacy in clearing bone marrow blasts. Our findings, although needing validation in larger and more homogeneous cohorts, may offer helpful clues in the management of aplasia of AML patients.
      Chemotherapy
      PubDate: Fri, 18 Sep 2020 10:50:47 +020
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 54.208.73.179
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-